Company Filing History:
1 out of 475 
1 out of 2,619 
1 out of 337 Years Active: 2022
Title: Kun-Young Park: Innovator in Tryptophan Hydroxylase Inhibition
Introduction
Kun-Young Park is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors that target specific metabolic pathways. His work has the potential to impact various medical conditions, making him a key figure in his area of expertise.
Latest Patents
Kun-Young Park holds a patent for a "Tryptophan hydroxylase inhibitor and pharmaceutical composition including same." This invention relates to a novel tryptophan hydroxylase inhibitor that exhibits an excellent inhibitory effect on TPH1. The inhibitor can be effectively utilized for the prevention or treatment of disorders associated with TPH1 activity, including metabolic disorders, cancer, and digestive or cardiovascular system disorders. Notably, this inhibitor shows promising treatment effects on inflammatory bowel disorders, making it a valuable asset in the pharmaceutical industry.
Career Highlights
Throughout his career, Kun-Young Park has been associated with prestigious institutions such as the Gwangju Institute of Science and Technology and the Korea Advanced Institute of Science and Technology. His work at these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Jin Hee Ahn and Hail Kim. Their collaborative efforts have likely enhanced the research and development of innovative solutions in the pharmaceutical sector.
Conclusion
Kun-Young Park's contributions to the field of pharmaceutical innovation, particularly through his patent on tryptophan hydroxylase inhibitors, highlight his role as a significant inventor. His work has the potential to lead to advancements in the treatment of various medical disorders.